Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | HRAS | P01112 | 1/20 | 0.42 |
| ▸ | KRAS | P01116 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | GSR | P00390 | 3/20 | 0.37 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 3/20 | 0.36 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL989592 | 0.93 | SLC6A9 (0.42) | CCR1HRASKRASSLC6A9CYP3A4 | |
| SCHEMBL989583 | 0.91 | CCR1 (0.41) | CCR1SLC6A9CYP3A4HTR7F2 | |
| SCHEMBL988781 | 0.89 | SLC6A9 (0.41) | CCR1HRASKRASSLC6A9CYP3A4 | |
| SCHEMBL990093 | 0.89 | MEN1 (0.48) | CCR1SLC6A9CYP3A4F2ALDH1A1 | |
| SCHEMBL989128 | 0.88 | ALDH1A1 (0.43) | CCR1SLC6A9CYP3A4F2ALDH1A1 | |
| SCHEMBL990369 | 0.88 | SLC6A2 (0.42) | SLC6A9CYP3A4F2 | |
| SCHEMBL990394 | 0.87 | SLC6A9 (0.40) | CCR1SLC6A9CYP3A4ALDH1A1 | |
| SCHEMBL990351 | 0.86 | SLC6A9 (0.43) | SLC6A9CYP3A4ALDH1A1 | |
| SCHEMBL988985 | 0.86 | SLC6A9 (0.38) | SLC6A9CYP3A4F2ALDH1A1 | |
| SCHEMBL989820 | 0.85 | KMT2A (0.47) | SLC6A9CYP3A4HTR7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105502-A1 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott BmbH & Co. KG (DE) | 2011-05-05 | — | — | US | disclosed |
| EP-2271625-A2 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott GmbH & Co. KG (DE) | 2011-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105502-A1 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | GOLT1B, SLC10A1, SUGT1 | CCR1 2958/4885HRAS 1499/4885KRAS 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.